Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market

Jul 27, 2020

10 likes | 12 Views

C-Met mutated NSCLC Market The total incident cases of C-Met mutated NSCLC in the 7MM was 16,658 in 2017. The C-Met accounted for approximately 4% of the total cases of NSCLC. In 2017, with 7,202 cases the United States had the highest number of C-Met mutated NSCLC cases among the 7MM, while Spain with 869 cases had the lowest registered cases. The market size of C-Met mutated NSCLC in the 7MM was found to be USD 186 Million in 2017, which is expected to increase during the forecast period 2017-2030. Increasing use of biomarker testing, increase in mutation specific trials activity, increasing incidence of C-Met mutated NSCLC are some of the key drivers for the C-Met NSCLC market. The key companies in the C-Met mutated NSCLC market includes Novartis, Merck, Janssen Pharmaceutical, Eli Lilly and Company, AbbVie, Symphogen, Takeda, Exelixis, Ipsen and others. For more detailed information, visit: https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market

DelveInsight

Download Presentation

Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D